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Abstract 
In several areas of clinical research it is common for trials to assign different sites of the participants’ 
bodies to different interventions. For example, a randomized controlled trial (RCT) comparing surgical 
techniques for correcting myopia may randomize each eye of a participant to a different operation. Under 
such bilateral (‘split-body’) interventions, the observations from each participant are correlated. It is 
challenging to account for these correlations at the meta-analysis level, especially when the outcome is 
rare. Here we present a meta-analysis model based on the bivariate binomial distribution. Our model can 
synthesize studies on patients who received one intervention at one body site, patients who received two 
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interventions at different sites, or a mixture of these two groups. The model can analyze studies with zero 
events in one or both treatment arms and can handle the case of incomplete data reporting. We use 
simulations to assess the performance of our model and to compare it with the bivariate beta-binomial 
model. In the case of bilateral interventions our model performed well and outperformed the bivariate 
beta-binomial model in all scenarios explored. We illustrate our methods using two previously published 
meta-analyses from the fields of orthopaedics and ophthalmology. We conclude that our model 
constitutes a useful new tool for the meta-analysis of binary outcomes in the presence of split-body 
interventions. 
Keywords: correlated outcomes; rare events; safety outcomes; bivariate binomial; Sarmanov family 
1 Introduction 
Correlated outcome data can occur in trials when multiple related outcomes are measured, when a 
single outcome is measured at multiple time-points or when patients receive more than one intervention. 
Typical examples of the latter category are the cross-over trials and the within-person randomized trials1. 
For example, outcomes from patients receiving different surgical operations for myopia in each of their 
eyes or different carpal-tunnel release methods in each of their arms are correlated.  We will refer to this 
kind of interventions as ‘split-body’ or ‘bilateral’ interventions. At the meta-analysis level, disregarding 
the correlation induced by bilateral interventions and analyzing observations as if they belong to different 
patients may affect the precision of the pooled estimates2–6.  
For the case of binary outcomes, if studies with bilateral interventions report the full, ‘cross-
classified’ information (number of events by patients and treatments) one can readily account for the 
correlations. This cross-classified information is however usually unavailable to the meta-analysts. If not 
available, an assumed value of the correlation between the arm-specific effects (e.g. the log-odds) can be 
imputed and the data can be synthesized using a bivariate normal likelihood.  
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While this approach might be reasonable for efficacy outcomes, it is problematic for safety 
outcomes. Safety outcomes are often rare and in this case the normal approximation performs poorly 
while the estimation of the between-study variance (heterogeneity) becomes challenging7. Moreover, the 
normal approximation of the log-odds or log-risks cannot be readily used in the presence of studies with 
zero events in one (‘single-zero’ studies) or both arms (‘double-zero’ studies). Such studies are frequently 
encountered in meta-analyses: in a sample of 500 Cochrane reviews, 30% included at least one single-
zero, while 34% of these reviews included at least one meta-analysis with a double-zero study8,9. In such 
cases researchers usually resort to performing a ‘continuity correction’ i.e. they add a factor in each cell 
of the corresponding two-by-two table. The choice of the factor, however, may heavily affect the meta-
analysis estimates10,11 and might lead to paradoxical results12. Double-zero studies are typically excluded 
from meta-analysis8. 
Alternative meta-analysis models that do not require a continuity correction and do not exclude 
studies have been suggested. These include generalized linear mixed models13, using the arcsine 
difference14, a Poisson-Normal model15, a zero-inflation model16, a Poisson-Gamma model17, Firth’s 
logistic regression model18 and a bivariate beta-binomial model19–21 (sometimes called Sarmanov beta-
binomial model). Kuss8 reviewed and compared ten different methods for meta-analysing rare events in a 
simulation study and recommended the use of the beta-binomial model for the meta-analysis of rare 
events. None of the aforementioned methods, however, can account for correlations induced by bilateral 
interventions.  
Although there are methods available for meta-analysing correlated binary outcomes, it is not clear 
whether they are appropriate when the outcome is rare and when reporting is incomplete. In this paper we 
propose a new model fitted within a Bayesian framework that can be used to meta-analyse studies of 
unilateral design (each patient received one intervention in one body part), bilateral design (all patients 
received two interventions in different body parts) or a mixed design (where some patients received one 
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intervention and some patients both). Our model uses a bivariate binomial likelihood that explicitly 
accounts for the correlations induced by the presence of bilateral interventions without employing the 
normal approximation. Our model can accommodate a meta-analysis in the presence of rare events, 
without excluding single- or double-zero studies from the dataset, and can handle the case of incomplete 
reporting in the original studies, i.e. when cross-classified information is not provided.  
The paper is structured as follows. In Section 2 we describe the datasets from orthopaedics and 
ophthalmology we use to exemplify our methods. We chose these particular examples because they 
include studies of different designs and they cover both the case of rare and common outcomes. In 
Section 3 we present our model, and discuss how it can be applied for the case of studies of different 
designs. In Section 4 we present results from simulations that we conducted in order to assess the 
performance of our model and to compare it with the previously recommended beta-binomial model. In 
Section 5 we present results from the examples. Finally, in the Discussion section we highlight our main 
findings, summarize the strengths and weaknesses of our approach and discuss possible extensions.  
2 Example datasets 
2.1 Two surgical treatments for carpal tunnel syndrome  
Our first example comes from a Cochrane review22 that compared the endoscopic release vs. any 
other open surgical intervention for carpal tunnel syndrome (CTS). CTS is a painful compression of a 
nerve at the root of the hand. One of the safety outcomes was the occurrence of minor complications 
(such as numbness around the incision or superficial infection) reported in 24 studies. Minor 
complications were rare: 5 out of 24 studies were single-zero and 4 were double-zero. In Section 1.1 of 
the Appendix we provide a detailed description of the data. We categorize the 24 studies in four different 
types, depending on their design and reporting: 
• Unilateral design (studies 1-12): patients received one intervention, in one of their arms. Studies 
report number of patients and number of events per intervention group. 
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• Bilateral design (studies 13-15): each patient received both interventions, in different arms. In 
the CTS example these studies reported number of patients and number of events per 
intervention group. They did not report cross-classified information (e.g. number of patients with 
events in both of their arms, with events in none of their arms, with events in one of their arms) 
• Mixed design (studies 16-22): some patients received one intervention in one of their arms, and 
some patients received both in different arms. In the CTS example, these studies reported the 
corresponding number of patients in each group (or we calculated them from the reported data). 
No cross-classified information was reported. 
• Unknown design (studies 23-24): these studies only report number of events and number of 
treated arms, per intervention group. They do not provide information on how many patients (if 
any) received both interventions in both of their arms.  
2.2 Two surgical techniques for correcting myopia 
Our second example comes from a Cochrane review for the comparison of Laser-assisted in-situ 
keratomileusis (LASIK) versus photorefractive keratectomy (PRK) for myopia23. The outcome of interest 
is the proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better, at six months after 
treatment. Ten studies reported this outcome. Two studies had a unilateral design, five studies had a 
bilateral design and did not report any cross-classified information and three studies had an unknown 
design, i.e. they did not report the exact number of unilateral and bilateral interventions. We present the 
data for this example in Section 1.2 of the Appendix. Table 1 summarizes the type of data that were 
available for each example and introduces notation. 
<TABLE 1 HERE> 
3 Methods 
In this section we present our random-effects meta-analysis model that can be fit within a Bayesian 
framework. Methods for estimating and summarizing treatment effects from studies of unilateral and 
Page 5 of 68
https://mc.manuscriptcentral.com/smmr
Statistical Methods in Medical Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
bilateral design are established and we start by revising them. However, the number of events per patient 
and intervention (the cross-classified information) is required for a proper analysis of studies of bilateral 
design. Such information is often not available. We introduce a model that bypasses this problem, and 
then we extend it for the analysis of studies of mixed and unknown design. In Section 3.6 we discuss 
approaches for formulating prior distributions for all model parameters. We only consider the case of a 
binary outcome, i.e. each patient can only have up to one event per intervention. 
3.1 Unilateral design 
Let’s assume that a study  compared interventions A and B, and that it applied only unilateral 
interventions. Let us assume , (,) patients received intervention A (B), and that we observed , 
(,) events. Given that each patient only received one intervention, the events are independent and we 
can assume two univariate binomial distributions. The estimated probabilities of event in each 
intervention group of each study can be used to estimate study-specific intervention effects, with their 
corresponding standard errors. These study-specific estimates can be synthesized at a second stage, under 
a usual meta-analytical model. This corresponds to a two-stage meta-analysis model. The drawback of 
two-stage models is that in the second stage the study-specific intervention effects are assumed to follow 
a normal distribution, and that the variances are assumed to be exactly known24. This implies that a two-
steps approach is generally suboptimal for the case of binomially distributed data, and even more so when 
the data are sparse.  
Alternatively, we can do the meta-analysis in a single step using a hierarchical model. A one-step 
model can be written as follows: 
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,~	
,, ,, ,~	
, , , 
, =  + 2 , , =  −

2  
~(, ) 
 , , ~…	(	 !
 ) 
(1) 
where	 is the study-specific log-odds ratio,  is the summary log-odds ratio and	 the heterogeneity 
variance.   is a nuisance parameter that corresponds to the log-odds of the mean event rate in both 
intervention groups (we will refer to this quantity as “average risk” throughout this paper). For  , 	and  
prior distributions are required. An alternative, one-stage model can be formulated by assuming 
exchangeability on the average risk: 
,~	
,, ,, ,~	
, , , 
, =  + 2 , , =  −

2  
~(", #"), ~(, ) 
", , , #"~…	(	 !
 ) 
(2) 
The advantage of model (2) is that in the case of rare events it facilitates the estimation of the 
parameters by “borrowing strength” for the average risk across studies. The price to pay is that the model 
makes an additional assumption, i.e. the exchangeability of average risk across studies. Note that one can 
write alternative one-stage models, e.g. by assigning a prior to , or , instead of . We discuss this 
assumption more in the Discussion. 
3.2 Bilateral design: studies providing cross-classified information 
Let us assume that study  compared interventions A and B and that each patient received both 
interventions. Let us also assume that the study reports the full cross-classified information, as shown in 
Table 2. For simplicity, in what follows we drop the study index. 
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<TABLE 2 HERE> 
From this table we can estimate the probability of an event in each treatment. E.g. by maximizing 
the likelihood we estimate ̂ = /, ̂ = /, and also ̂& = 
&/, where ' = 1,2,3,4. If we choose 
odds-ratio as an effect size, we have	+,- = (̂) − (̂). Observations ( and ) belong to 
the same patients, which means that the estimates for the two probabilities ̂ and ̂ are correlated 
within each study. The estimated  ./0 +,-  should thus include a covariance term: 
./0 +,-  = ./0 (̂) + ./0 (̂) − 2	1.2 ((̂), (̂)) (3) 
This covariance term can be written as a function of Pearson’s 3 coefficient25, which is a measure of the 
correlation between two binary variables of a 2 × 2 table26: 
35 = ̂6̂7 − ̂̂89	̂(1 −	 ̂)̂(1 − ̂)
 (4) 
If we ignore the cross-classifications (
6, 
, 
8 and 
7) and use only the margins of Table 2, we 
treat the two intervention groups as if they were independent. In that case the variance of the effects will 
not account for any covariance. This, in turn will lead to the precision of the estimated relative effects 
being either inflated or deflated, depending on the underlying correlation between  and . In most 
clinical examples we would expect a positive correlation, so ignoring this correlation is generally 
expected to lead to less precise results. 
In order to correctly account for this covariance we need to use the full information and to employ 
a multinomial likelihood: 
(
6, 
, 
8, 
7)~:
;/(6, , 8, 7; ) (5) 
We can then estimate ̂6, ̂, ̂8	and ̂7, and we can identify ̂ = ̂6 + ̂ and ̂ = ̂6 + ̂8, and 
calculate their covariance. At the meta-analysis level, we can use model (2) with a multinomial instead of 
a binomial likelihood.  
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For this analysis one would need to have the cross-classified information of Table 2. Alternatively, 
if the study has performed an appropriate analysis, one could use the reported results (e.g. standard error 
or p-value) to reverse-engineer Equation (3) so as to calculate the entries of Table 2 and then use the 
correct multinomial distribution of Equation (5). To our experience, published studies rarely report the 
information needed for such back-calculations. To make matters worse, some of the studies may include a 
mixture of unilateral and bilateral interventions, often without reporting the corresponding numbers. In 
the following sections we show how to correctly analyze the data in such circumstances. We start by the 
simplest cases of data availability and move on to more complex situations.  
3.3 Bilateral design: studies that do not provide cross-classified information 
Let us assume a bilateral study where only the margins of Table 2 are reported (i.e. ,   and ). 
The exact likelihood of the marginal data (i.e. ,  and ) is given by Gonin and Aitken in the form of a 
bivariate binomial distribution27–29. More specifically, the probability of having 	events in intervention 
group A and   events in B, in a total of 	patients that received both interventions is given by: 
=( , ) = > !
6! ( − 
6)! ( − 
6)! ( −  −  + 
6)!		
@AB	(CD,CE)
FGH@IJ	(K,CDLCEMN)	
 
× 6FGCDMFG8CEMFG7NMCDMCELFG 
(6) 
where 6, , 8 and 7 = 1 − 6 −  − 8 are the probabilities corresponding to each cell of Table 1.  
Equation (6) runs through the total number of different set-ups of the contingency table that give 
rise to the same margins  and  . One could in principle assume an uninformative prior for 6, , 8 
and 7 (e.g. through a uniform Dirichlet distribution) and then use the likelihood of Equation (6) to obtain 
the posterior distribution for these four probabilities. As discussed in the previous section, the estimation 
of the relative effects between the two interventions would use ̂ = ̂6 + ̂ and ̂ = ̂6 + ̂8. This 
would induce a correlation between the estimates of  and . 
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However, this approach would result to an average of all possible values for this correlation.  It 
might be the case, however, that having an event in A is highly correlated with having an event in B. This 
could happen when for instance events are induced by the presence of a certain characteristic in the 
patient, irrespective of intervention received. In the CTS example, it might be the case that patients with 
manual labour professions are more prone to having a minor complication in both arms. In such cases, 
there would be a strong underlying correlation, which would not show in this approach. A hypothetical 
example to clarify this point is presented in Figure 1, where a study of 100 bilateral interventions reports 
60 events in intervention A and 70 in B, but no information on the cross-classification. The likelihood of 
Equation (6) sums across all possible contingency tables: from those that correspond to a high correlation, 
like the one with 
6 = 60 in Figure 1 (3 = 0.80), up to those that correspond to a strong negative 
correlation like the bottom configuration in Figure 1 (where 3 = −0.53). I.e. Equation (6) incorporates a 
correlation of  and  based on the average of all possible values of 3. Essentially, the estimates for  
and  are correlated in a study of a bilateral design, but one cannot estimate this correlation using only 
the margins of the 2x2 table.  
In order to use an informed account of the correlations while employing the correct likelihood of 
the data described in Equation (6) we instead utilize external information for 3. In Section 3.6 we discuss 
how to formulate prior distributions for this quantity based on external data or expert opinion. Given , 
 and 3 we calculate 6 = 	 + 39(1 − )(1 − ),  =  − 6, 8 =  − 6 and 
7 = 1 − 6 −  − 8. This method allows for an informed reconstruction of the full contingency table. 
This is performed in a stochastic way: more plausible configurations (according to the prior) are given a 
higher probability. Note that given a set of values for  and , 3 is bounded between a minimum and a 
maximum value30,31. Thus, after drawing values for the model’s parameters from the corresponding prior 
distributions, values the prior distribution for 3 need to be appropriately truncated. Finally, note that 
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when one (or more) of the margins is 0, then the contingency table can be reconstructed with certainty. 
For the reader’s convenience we provide the full likelihood of the model in the Appendix, Section 2. 
An alternative method for reconstructing the 2x2 table uses the odds-ratios of the cross-classified 
information instead of 3. The advantage of this method is that it does not require any truncation. The 
disadvantage is that it is less easy to formulate clinically meaningful priors for the parameters. Details on 
this alternative approach are presented in Section 3 of the Appendix. 
<FIGURE 1 HERE> 
3.4 Mixed design 
We now move on to the situation where a study includes a mixture of bilateral and unilateral 
interventions (mixed-design studies). For including this type of studies in the analysis we will make one  
extra assumption. We will assume that in each such study the probability of having an event when 
receiving a specific intervention is the same in patients receiving unilateral interventions (patients 
receiving only that intervention) and bilateral interventions (patients receiving both interventions): 
"FT = UTVW(XL|BL)	UTVW(	L) + UTVW(XL|BM)	UTVW(	M) ≡ . This assumption might not hold if 
there is an interaction between the two interventions, for patients that received both. In such case 
additional assumptions would be needed. Note that for the case of zero correlation we would have 
UTVW(XL|BL) = UTVW(XL|BM).  
In what follows we suppress the study index. Let us start by assuming that such a study provides 
all relative information, i.e. the number of patients who only received intervention A, the number of 
patients who only received B, as well as the number of patients that received both A and B; also, the 
number of events for each of these three patients groups, and the full cross-classifications for the bilateral 
interventions. We can estimate relative effects from such a study by employing the methods described in 
the previous sections, namely two independent binomial likelihoods for the unilateral interventions in A 
and B, and a multinomial likelihood as in Equation (5) for the bilateral ones. If no information on the 
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cross-classifications is available, likelihood (6) needs to be used instead, together with some external 
information on the correlation coefficient. According to our assumptions, these three groups inform only 
two probability parameters,  and .   
Let us now focus on an even more complicated scenario, which also corresponds to the seven 
mixed-design studies in the CTS example. More precisely, let us assume that such a study provides 
information on the events on each intervention ( , ), the total number of patients receiving each 
intervention (, ), and the total number of patients in the study (). The number of events and the 
number of patients with a unilateral intervention (A and B), and the number events and patients with a 
bilateral intervention are not reported. 
We first need to calculate the number of patients that received unilateral and bilateral 
interventions, using the reported data. Let us keep in mind that each patient can have a maximum of one 
event per intervention. Let us denote " (") the number of patients that received only intervention A 
(B). Let U denote the bilateral interventions, i.e. the number of patients that received both A and B. 
Obviously " +" + U = . It also holds that " + U =  and " + U = . By solving this set 
of equations we find the number of patients in each group, i.e. " =  − , " =  −  and U =
 +  − . 
We do not have information on how the  events in intervention A are divided among the " 
patients who received only A and the U patients who received both A and B. Let us assume that \ out of 
these  events were in the " patients; the rest  − \ were in the U	bilateral cases. Obviously it should 
hold that \ < ". Also  − \ <	U,	i.e. the number of events in the bilateral interventions group must 
be smaller than the total number of patients in that group. Of course \ ≥ 0 and also \ ≤ . All these 
constraints are summarized in the following double inequality: max(0,  − U) ≤ \ ≤ min	(", ). 
Likewise, if we denote by e the number of patients who only received intervention B and had an event, it 
holds that max(0,  − U) ≤ e ≤ min	(", ).  
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We also do not know how the  − \ and  − e events observed in patients who received bilateral 
interventions are cross-classified in a 2 × 2 contingency table, like the one in Table 1. In Figure 2 we give 
a graphical analysis of the possible ways that the observed events may be distributed in each category of 
patients. 
Quantities \, e and 
6 of Figure 2 are not reported. In order to write the exact likelihood of the 
reported data (, , ,   and ), we will combine the likelihoods of all possible configurations that 
lead to these observations, as presented in Figure 2. Since \ and e correspond to events in different 
groups of patients, they follow independent binomial distributions i.e. \~	
(, ") and 
e~	
( , "). For the events in the group of patients with bilateral interventions we follow the analysis 
of Section 3.3 and we can write the likelihood after carefully adjusting Equation (6). The full, exact 
likelihood of the observed data (, ) can be written as: 
=( , ) = > > f
"
\ g 
h(1 − )NDiMh j
"
e k 
l(1 − )NEiMl	
@AB	(NEi,CE)
lH@IJK,CEMNm
@AB	(NDi,CD)
hH@IJK,CDMNm
 
× > 
U!

6! ( − \ − 
6)! ( − e − 
6)! (U −  −  + \ + e + 
6)!		
@AB	(CDMh,CEMl)
FGH@IJ	(K,CDMhLCEMlMNm)	
 
× 6FGCDMhMFG8CEMlMFG7N
mMCDMCELhLlLFG. 
(7) 
This likelihood is a generalization of the cases described in Section 3.1 (unilateral interventions 
only) and 3.3 (bilateral interventions only). It is easy to see that this likelihood decomposes into a simple 
product of two independent binomials if we set U = 0 (in which case \ =  , e =  and 
6 = 0): this 
corresponds to the case where there are no bilateral interventions. It is also straightforward to see that if 
we set U =  then " = " = \ = e = 0 and the likelihood of Equation (7) reduces to the one of 
Equation (6), as expected. A more detailed description of this model can be found in Section 4 of the 
Appendix. 
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The joint posterior distribution for n and o includes their correlation. The extent of this 
correlation depends on (i) the number of patients who received bilateral interventions in the studies, 
where zero bilateral interventions will mean zero correlation, and (ii) the prior distribution used for 3. 
<FIGURE 2 HERE> 
3.5 Unknown design 
A study of this type reports  , ,  and , but does not provide any information on the total 
number of patients. This implies that there is no (exact) information on how many of the included patients 
received unilateral and how many bilateral interventions; but meta-analysts might have reasons to suspect 
that at least some of the patients in these studies received both interventions. 
The lack of more information from these studies means that researchers cannot use the methods 
described in the previous sections to take into account correlations in the estimation of relative 
intervention effects, unless some strong assumption is employed, i.e. on the percent of bilateral 
interventions in the study. The simplest approach for the analysis is to assume two independent 
binomials. As we discussed, this may lead to over- or under-precision in the estimated relative 
intervention effects if the correlation is non-zero.  
The two extreme cases for such a study are (i) there are no bilateral interventions, and (ii) there are 
a maximum number of bilateral interventions (= max	( , )). Given that information on this number is 
unavailable, when analyzing such a study researchers may want to use the most conservative estimate. 
This means that if  and  are expected to be positively correlated in bilateral interventions, the analyst 
should analyze a study of unknown design as if all patients received only one intervention, i.e. as if the 
study was unilateral. If instead researchers are instead interested in obtaining the most liberal estimates, 
they should assume that a large number of interventions might be bilateral (maximum value is 
max( , )). These considerations need to be reversed for the (perhaps less relevant) case of having a 
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negative correlations. In any case, a sensitivity analysis is warranted to explore the effect of the 
(unknown) study design in the overall, pooled effect. 
In Section 5 of the Appendix we provide a summary table of how to choose the likelihood for each 
study, depending on its design and on the information it provides.  
3.6 Formulating informative prior distributions 
In what follows we discuss how meta-analysts can augment the information included in the studies 
using external information in the form of informative prior distributions for the model parameters. We 
focus on one-step meta-analysis models. We discuss the following parameters: the heterogeneity 
variance, the mean and variance of the average risk, and the correlation (3 coefficient).  
Heterogeneity 
In a recent meta-epidemiological study by Turner et al. 32, the authors re-analysed data from 
around 15,000 binary outcome meta-analyses from the Cochrane Database of Systematic Reviews. 
Results were used to create informative predictive distributions for  33. These prior distributions cover 
80 different settings, categorized by the outcome being assessed, the types of interventions being 
compared, etc.  
Average risk 
The optimal source of information for this parameter would be to use eligible RCTs that were 
excluded from the original meta-analysis due e.g. to inadequate reporting of effect sizes. This would 
allow researchers to obtain a realistic estimate of the mean and variance of the (logit-transformed) 
average risk in order to formulate priors that can be included in the model. Alternatively, one could use 
observational studies (such as registries or large cohort studies). Note however that in order to formulate a 
prior distribution for the variance (parameter #" in Equation (2)), one would need to include multiple 
studies. If no external source of information is readily available, then a prior distribution can be elicited 
from the experts, following a method described in 25,34. In Section 6 of the Appendix we discuss the 
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details of this method, i.e. how researchers can elicit information and how they can synthesize 
information obtained from multiple experts (after possibly weighting each expert’s opinion, e.g. for the 
years of experience on the field, or the number of studies he/she has been involved in).  
Correlation 
If some of the studies report full, cross-classified information (as described in Section 3.2), then 
the corresponding estimates of the correlation coefficients can be used to formulate an informative prior 
distribution for the analysis of the rest of the studies. Alternatively, one can formulate priors by eliciting 
information from expert clinicians. In a previous work we describe how to elicit information on 
correlation indirectly, using a conditional probability25. Here, we propose a more straightforward method. 
As shown empirically by Clemen et al.35, directly asking for the correlations is a reasonable approach, 
often more accurate than indirect methods. More detail on how to synthesize information from multiple 
experts in order to construct a prior distribution for 3 can be found in Section 7 of the Appendix. The 
method uses the Fisher transformation to synthesize information, p = 6 log f
tL6
6Mtg. If there is no usable 
external information for 3, researchers can use a minimally informative prior 3~u(0,1) if the correlation 
is generally expected to be positive (and conversely 3~u(−1,0) if it is expected to be negative).  
It is unclear whether the choice of the prior distribution for the different parameters of our model is 
equally important, and whether researchers should focus on obtaining informative priors for some of the 
parameters rather than others. It is also unclear what would be the impact of using misspecified prior 
distributions to our model estimates. Lambert et al.36 showed that in general the choice of scale 
parameters (such as standard deviations) is more important than the choice of location parameters in 
Bayesian analyses with sparse data. As we will see in the next section, this agrees with the findings of our 
simulations. There we discuss that heterogeneity is the most influential parameter in our model. Using an 
informative prior for heterogeneity can greatly increase precision and enhance the power of the model. As 
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we will also see, using minimally informative (or even misspecified) priors for the rest of the parameters 
may have a smaller impact on the model’s performance.  
4 Simulations  
4.1 Data generation procedure and description of the scenarios  
We performed a small-scale simulation study to assess the performance of the model we proposed 
in this paper. We limited the simulations to the case of studies with bilateral design  where only the 
marginal numbers of events are reported, and among which there is variability (heterogeneity). We 
explored a range of different scenarios. For each scenario we simulated 100 datasets, with each dataset 
corresponding to an independent meta-analysis.  
Scenarios 1-20 aimed to compare our model with the bivariate beta-binomial model. This model 
has been previously recommended for meta-analyzing rare events8. For these scenarios we simulated 20 
studies for each meta-analysis. Two additional scenarios (21 and 22) aimed to explore the importance of 
specifying informative priors for the parameters of our bivariate binomial model. For these scenarios we 
simulated 10 studies for each meta-analysis, aiming to increase the impact of the prior distributions.  
To generate data, for each scenario we first defined the true relative treatment effect on the log-
odds ratio scale (), the log-odds of the average risk of event and its standard deviation (", #") and also 
the correlation between the events (3). For each independent meta-analysis we sampled the variance of 
random effects from a log-normal distribution: ~LN(−2, 1.5)33. Suppressing the study index for clarity, 
for each study we sampled the study-specific treatment effects, ~	(, )	and the log-odds of the 
average risk, ~(", #"). We simulated the number of patients () in each study by drawing from a 
uniform distribution, U(50,100). 
Using , 	and 3 we calculated the probabilities 6, , 8 and 7 (corresponding to 
6, 
, 
8 and 

7 of Table 2).  Using these four probabilities and the number of patients per study we generated the 
number of events of the 2x2 cross-classified table by drawing from a multinomial distribution. We then 
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calculated , ; together with , these are the only data that were supposed to be available from the 
study.  
We explored scenarios using the following values for the simulation parameters:  
•  = 0, 0.5. 
• 3 = 0.30	(p = 0.31, low correlation) and 3 = 0.60	(p = 0.69, high correlation). 
• " = −1.5, #" = 0.5: in these scenarios there were almost no single- and double-zero 
studies (<1%). " = −3.0, −3.5 and #" = 1.0:  these scenarios have some single- and 
double-zero studies (0 – 30% in total). " = −4.0, #" = 1.0 and " = −3.0, #" =
3.0: these scenarios have many single- and double-zero studies (more than 30% in 
total).  
We generated all data in R37, code is provided in the Appendix, Section 8.  
4.2 Analyses of the simulated datasets 
The simulated datasets were analyzed using the bivariate binomial model discussed in Section 3.2. 
The model is also presented in more detail in Section 2 of the Appendix. We performed our analyses in 
OpenBUGS38,39, the code is available in Section 9 of the Appendix. For each analysis we simulated a 
single chain of 20,000 samples, and we discarded the first 5,000 samples. This was deemed to be 
sufficient based on some initial runs and also after visually inspecting the posterior distributions40.  
For the analysis of scenarios 1-20 we chose between using weakly informative prior distributions 
centered near the true value of the parameters, vague priors and misspecified priors for the correlation. 
These choices are described in detail in Table 4 of the Appendix (Section 10.1). In addition, these 
scenarios were analyzed using the bivariate (Sarmanov) beta-binomial model, which accounts for 
correlations in the 2x2 tables 21. For this we used a routine in R37 provided by Chen et al.21. We also 
checked results by comparing with results obtained from the mmeta package in R, which also implements 
the beta-binomial model 41.  We compared our model with beta-binomial in terms of (a) mean bias; (b) 
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mean squared error (MSE) (the mean of the squared bias); (c) empirical coverage (the percent of meta-
analyses that included the true effect in their 95% credible interval (CrI)); (d) empirical power (percent of 
meta-analyses that rejected the null hypothesis of no treatment effect, when the true treatment effect was 
non-zero); and (e) the gain in precision (bivariate binomial model over beta-binomial model). This was 
calculated as the percentage reduction of the mean width of the 95% Credible Interval obtained from our 
model as compared to the 95% Confidence Interval from the beta-binomial model. The datasets generated 
under scenarios 21 and 22 were analyzed multiple times, using only the model presented in this paper. 
Each dataset was analyzed using first vague priors for all parameters, and then using vague priors for all 
model parameters except for one at a time. Details can be found in Table 5, Section 10.2 of the Appendix.  
4.3 Results from the simulations 
The results from the analyses of scenarios 1-20 are presented in Table 3. Regarding the 
interpretation of results, and taking scenario 1 as an example, we can see that our model had a slightly 
larger mean bias for the logOR than the bivariate beta-binomial (0.012 vs 0.001), and also a slightly 
larger MSE (0.024 vs. 0.018). However, the CrIs obtained from our model were narrower than the CIs 
obtained from the bivariate beta-binomial model. Thus, coverage for the former model was 95% while for 
the latter it was 99%. By comparing the precision of the two models (quantified by the width of the 
corresponding credible/confidence intervals) we calculated a 29% increased precision of our model as 
compared to the bivariate-binomial. 
Simulations showed that our model performs markedly better than the beta-binomial model in 
most scenarios we explored. In almost all cases our approach led to smaller mean bias and similar MSE. 
Coverage probability was closer to the nominal 95% in our approach for most scenarios. Our model led to 
an increased precision of the estimates. This increase in precision, quantified as the percentage reduction 
of the width of the 95% CrI, ranged from 29 to 44% in all scenarios. Our approach performed much better 
in scenarios with many single- and double-zero studies, when we assumed non-zero log-odds ratios. In 
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these settings the beta-binomial model had very low power to detect a relative treatment effect. Our 
simulations showed that in the presence of bilateral interventions, even when the prior distributions are 
only mildly informative or misspecified, the bivariate binomial model performs better than the bivariate 
beta-binomial (Scenarios 13-16). 
Another interesting finding in our simulations was that for the case of non-zero relative treatment 
effects and large heterogeneity in the average risk (Scenarios 17-20), the beta-binomial model was very 
inefficient. In these scenarios this model showed excessive bias, and in all cases the bias was towards zero 
treatment effects. Moreover, there was large MSE, insufficient coverage and minimal power. This was the 
case even under zero correlation scenario, i.e. for the usual unilateral design (Scenario 20). This finding 
comes in contrast with the recommendations by Kuss8, i.e. to use the beta-binomial model for all meta-
analyses of rare events. But, in his simulations8, Kuss did not explore the scenario of large heterogeneity 
in the average risk of an event.  In a somewhat different context (meta-analysis of proportions, not 
relative effects) Ma et al. showed that the beta-binomial model performs worse when the event rates are 
relatively large (e.g. >5%)42. 
 In Table 4 we present the results from the analysis of data simulated under scenarios 21 and 22, 
using different priors for the model’s parameters. Results suggested that the most influential prior is the 
one for heterogeneity. Using an informative prior distribution for  instead of a vague one greatly 
enhanced the performance of the model in terms of bias, precision, coverage and power. Using 
informative priors for the other model parameters had a smaller impact in all scenarios explored. 
<TABLE 3 HERE> 
<TABLE 4 HERE> 
5 Applications 
In this section we show results from applying our methods to the two examples presented in 
Section 2. We used the following models for the analysis:  
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i. Univariate fixed-effects meta-analysis (UNI-FE), i.e. we used model in Equation (2), but 
omitting the random effects distribution. This analysis ignores the correlations due to bilateral 
interventions. We fitted this model in a Bayesian as well as a frequentist setting, using 
maximum likelihood estimation (MLE).  
ii. Univariate random-effects meta-analysis (UNI-RE), using the model in Equation (2). This 
analysis ignores the correlations due to bilateral interventions. We fitted this model in a 
Bayesian as well as a frequentist setting, using MLE. 
iii. Bivariate binomial, fixed-effects meta-analysis (BB-FE): we used the model described in this 
paper accounting for the correlations due to bilateral interventions, as discussed in Sections 3.3 
and 3.4. We omitted random effects. 
iv. Bivariate binomial, random effects meta-analysis (BB-RE): the same as in model iii, but also 
including random effects 
v. The bivariate beta-binomial model. Note that this is by definition a random effects model. 
We provide the OpenBUGS code in Section 11 of the Appendix. In Section 12 of the Appendix we 
provide codes for fitting the model in R using the R2WinBUGS package43, and for fitting the model of 
Equation (2) in a frequentist setting. We performed 20,000 iterations, and we discarded the first 5,000 
samples. We fitted the bivariate beta-binomial model in R21. We fitted all models using a conventional 
laptop computer. The run-time required for fitting our bivariate binomial model was around 23 minutes 
for the CTS example and less than a minute for the myopia example.  
5.1 Surgical operations for CTS 
Two studies in this dataset had unclear design. We analyzed these studies as if they were of 
unilateral design following the arguments presented in Section 3.5 as we expect a positive correlation 
between complications in two arms of the same patient. 
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For models i to iv we assume a vague prior "~u(−6, 0) for the log-odds of the mean event rate, 
#"~u(0, 3) for the corresponding variance, and ~u(−2, 2) for the log-odds ratio. For the random-
effects models (models ii and iv) we use informative priors from the empirical distributions for a safety 
outcome for non-pharmacological interventions log() ~(−1.43, 1.45) provided in 33. For the 
bivariate models (iii and iv), we perform two analyses: one assuming a low correlation between the 
outcomes, p~(0.2, 0.1), and one assuming a moderate-high correlation, p~(0.5, 0.1). Results are in 
Figure 3. The BB-RE model with moderate-high correlation was assumed to be our primary model, the 
rest of the models can be seen as sensitivity analyses. For the primary model, the posterior median 
estimate for " was -3.41 (-4.35, 2.56) and for #"was 1.93 (1.33, 2.80). 
The endoscopic surgical operation was found to be more safe than the open in all analyses. When 
switching from the univariate to the bivariate model the increase in precision was rather small, especially 
when a low correlation was assumed. This should come as no surprise, as only 13% of the patients in this 
meta-analysis received bilateral interventions. One interesting observation was that when we increase the 
assumed correlation in the BB-RE scenario the estimate and CrI. for the odds ratio remained unchanged. 
This is because the increased precision in study-estimates is accompanied by an increase in the estimated 
heterogeneity. All implementations of the bivariate binomial model were more precise than the beta-
binomial model. Comparing the Bayesian and frequentist implementations of the UNI-RE model, we see 
some differences, which reflect the impact of the prior distributions. E.g. the MLE estimate for  in the 
UNI-RE (F) model was 0.83, while for UNI-RE (B) the median of the posterior median for  was 0.75. 
This difference was due to the impact of the informative prior distribution, which has median 0.48, thus 
pulling the MLE estimate towards lower values. The estimate for the odds ratios was also slightly 
different (0.50 for the Bayesian implementation vs. 0.52 for the frequentist). This difference can be 
attributed to the prior used for logOR, which was centered at 0, thus pulling the MLE estimate to lower 
values. 
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In order to assess the impact of the prior distributions in our results, we did a sensitivity analysis 
for model iv (BB-RE) with low correlation. Assuming vague priors for , " and #" had an immaterial 
impact on the results. However a less informative prior for the heterogeneity ( ~u(0, 2)) considerably 
increased imprecision in the treatment effects. This highlights once more the importance of using 
informative prior distributions specifically for the random effects variance parameter. 
Finally, as we argued in Section 3.3 the only information the data carries for the correlation coefficient 
ζ is the range of the allowed values within each study determined by the marginal total counts (as also 
depicted in Figure 1). As a result, the posterior estimates for ζ are entirely determined by their prior 
distributions. 
<FIGURE 3 HERE> 
5.2 Surgical techniques for correcting myopia 
Two studies in this dataset had unclear design. We analyzed these studies as if they were of 
unilateral design assuming a positive correlation. We used the following prior distributions for the model 
parameters:	"~u(−5, 5); #"~u(0, 5) and ~u(−2, 2). For heterogeneity we use an informative prior 
distribution log()~(−1.69, 1.68) based on the empirical evidence 33. We explore two options for 
correlation, p~(0.2, 0.1) (low correlation), and p~(0.5, 0.1) (moderate-high correlation). Results 
are presented in Figure 4. For our primary model, the posterior median estimate for " was 1.35 (-0.16, 
2.99) and for #"was 2.20 (1.34, 3.90). 
Accounting for correlations using our approach led to an increase in precision of the pooled 
estimates. For the case of random-effects model, some of the increase in precision was again 
counterbalanced by an increase in the estimates for , as in the CTS example. There are some 
differences between Bayesian and frequentist implementations of the UNI-RE model, particularly for . 
Heterogeneity was estimated to be 0 in the frequentist implementation, while in the Bayesian approach 
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the median posterior  was 0.29. This difference is again due to the effect of the informative prior 
distribution (which had a median of 0.43).  
The odds ratio estimated from the beta-binomial model was 1.00 (0.94, 1.06). This finding was 
markedly different to the results from all bivariate binomial models. It was also in disagreement with the 
frequentist analysis performed in the original publication; the authors performed a Mantel-Hanszel fixed-
effects meta-analysis resulting into OR=1.40(1.00, 2.00), which is in broad agreement with bivariate 
binomial models.  
One explanation for this important discrepancy between beta-binomial and the other approaches 
lies in the distribution of the average risk in the included studies. The average event risk ranged from 8% 
to 97% in the included studies, despite the fact the relative treatment effect was not very heterogeneous 
(see Appendix, Section 1.2). In such situations the bivariate beta binomial model may be heavily biased 
towards zero, as shown in the simulations (Section 4, scenarios 17-20). Additionally, the bivariate beta-
binomial model was shown to perform well when the event rate is small; here it is on average 70%42. 
<FIGURE 4 HERE> 
6 Discussion 
In this paper we have presented a Bayesian meta-analysis model for synthesizing binary data 
obtained from a collection studies of different designs: studies of the usual parallel design, studies of a 
bilateral (split-body) design, and studies including a mixture of unilateral and bilateral interventions. Our 
model uses a bivariate binomial distribution that accounts for the correlations induced due to bilateral 
operations, and has several distinct advantages. It uses the exact likelihood of the data; it does not employ 
the normal approximation; it respects the randomization of the studies; it includes in the analysis data 
coming from studies with zero events in one or even both interventions, without a need for imputation. 
Our model has similarities with the bivariate beta-binomial (Sarmanov) model for meta-analysis (e.g. as 
described by Chen et al.21). The two models differ, however, in the model parametrisation and the 
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assumption of random effects. The bivariate beta-binomial model assumes random effects for the arm-
specific event probabilities while the mean log-odds ratio is not a parameter of the model. In our 
approach, random effects are assumed for study-specific log-odds ratios, and the mean log-odds ratio is a 
parameter directly estimated in the model. This feature allows us to assume an informative prior 
distribution for the log-odds ratio, based on available empirical distributions. 
The bivariate beta-binomial model has been previously suggested as the optimal approach for 
meta-analysing rare events8. Our simulations showed that our model may lead to significant increase in 
precision, coverage and power, and a decrease in bias, as compared to the bivariate beta-binomial model. 
Moreover, according to our simulations, the bivariate beta-binomial model was found to perform very 
badly when the baseline risk was very variable in the included studies, even when no correlation was 
assumed. This was also demonstrated in one of the two real data-sets we used to illustrate our methods. 
The increase of precision in our model is more pronounced in fixed-effects meta-analyses. In the random-
effects regime, increasing the precision of the study estimates by accounting for correlations can be partly 
counterbalanced by an increase in the estimate for heterogeneity. 
We set our model in a Bayesian framework. This allows the inclusion of external information for 
the model parameters. However, for the case of rare events inferences from Bayesian meta-analyses may 
heavily depend on the choice of prior distribution for the parameters – even when these are thought to be 
uninformative36. Due to this fact, the use of frequentist approaches instead of Bayesian approaches is 
sometimes advocated. We understand the reasoning behind this view; in this paper however, we argue in 
favour of a Bayesian approach. We think that the scarcity of information due to the rarity of events should 
not be seen as an argument against the use of Bayesian methods. On the contrary, we think that meta-
analysts should opt for using Bayesian methods when they have the opportunity to include high quality, 
trustworthy external evidence in the analysis.   
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The major limitation of our model lies on its complexity. The software code we provide might be 
computationally heavy when studies have very large sample sizes. This may be especially true if there are 
large, mixed-design studies in the dataset. Moreover, embarking into this complicated modelling will only 
make a difference in the estimates if the corresponding correlation is large. If the correlation is expected 
to be small (e.g. 3 < 0.2), then researchers can safely treat observations from patients that received both 
interventions as if they corresponded to different patients.  
In our model we assumed exchangeability on the average risk. This might be a very strong 
assumption to make, e.g. if there are large differences in the randomization ratio across studies. 
Alternatively, researchers can assume exchangeability in the probability of having an event in one of the 
interventions, , or , in Equation (2). Choosing between the two, however, might be important when 
the data are sparse. Thus, the choice should be ideally guided by the availability of trustworthy external 
information that can be used to formulate informative priors. Another limitation of our model is that it 
does not account for the ordering and timing of the treatments. E.g., there might be studies where the 
treatments were administered simultaneously and there might be studies where treatment A is given first 
and treatment B later, or vice versa, first B then A.  
One additional limitation of our model is that it cannot correctly account for correlations induced 
by patients that received the same intervention in multiple sites of their bodies i.e. a classical cluster 
design (e.g. the same intervention in both hands, both eyes, multiple teeth, multiple people in a 
household, etc.). This situation requires an extension of the approach described in this paper. Other 
possible extensions of our bivariate binomial meta-analysis model relate to the case of two correlated 
outcomes (for studies of the usual, parallel design), and for the meta-analysis of twin studies. Also, our 
model can be extended for the meta-analysis of the accuracy of multiple diagnostic tests. Finally, it would 
be interesting to explore the use of the non-central hypergeometric distribution15,44 for bilateral 
interventions, and compare it with the bivariate binomial approach described in this paper.  
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Dimou et al. 45 discuss an alternative method that can be used to fill the (unknown) cross-classified 
information in the contingency tables of studies that do not report it. Their method uses information from 
studies that report the full tables. When no studies report the full tables, the authors suggest the use of the 
iterative proportional fitting algorithm46, which is however based on strong assumptions. Both these 
methods do not account for uncertainty in the (unobserved) missing values of the contingency tables. 
Moreover, the methods described in that paper are not suitable to use in the case of rare events.  
A different approach to synthesizing data from studies with bilateral design is to only use 
information on the number of discordant pairs 2, i.e. the number of patients with an event in A but not in 
B, and the number of patients with an event in B but not in A. This approach, however, could not be used 
for the case where some studies in the meta-analysis are of a unilateral design, and/or some studies are of 
a mixed design. E.g. this approach could not have been used in the examples presented in this paper.   
To summarize, we think that the model we presented constitutes the best available method for 
meta-analysing binary outcomes in the presence of bilateral (split-body) interventions, and that its 
implementation is in practice straightforward. 
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Table 1: Summary of the type of data available for the CTS and myopia examples. rA (rB) denotes the 
number of events and NA (NB) the number of patients that received intervention A (B). With N we denote 
the total number of patients included in each study. 
Design 
Data provided in 
the studies 
# of studies 
available 
Unilateral design: Only one body part per 
patient was treated 
,  , ,   , 
 =  + 
CTS: 12 
Myopia: 2 
Bilateral design: Each patient received both 
interventions in different body parts 
,   , 
 =  =  
CTS: 3 
Myopia:5 
Mixed design: Mixture of unilateral and 
bilateral interventions; some patients received 
one intervention in one body part, some 
received both interventions in different body 
parts 
,  , ,  ,  
max(, ) ≤   <  +  
CTS: 7 
Myopia: 0 
Unknown design: No information on whether 
any patients received both interventions 
,   ,   
CTS: 2 
Myopia: 3 
 
 
Table 2: ‘Contingency’ table for a study of bilateral design with N patients, providing the full cross-
classified information. A
+
(A
-
) denotes events (non-events) in intervention A; likewise for treatment B. n1 
denotes the number of patients with events for both interventions. n2 is the number of patients with an 
event for A and a non-event for B, the opposite is n3. n4 denotes the number of patients with no events in 
any intervention. 
 
 
 
 {L {M Total 
|L 
6 
  
|M 
8 
7  −  
Total   −   
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Table 3: Results from 20 scenarios, comparing the proposed bivariate binomial model to the bivariate 
beta-binomial model. All scenarios are analysed using informative priors on φ for the bivariate binomial 
model, except otherwise noted. SZ (DZ): single (double)-zero studies. ‘Some SZ/DZ’ denotes scenarios 
with 0-30% SZ/DZ studies. ‘Many SZ/DZ’ denotes scenarios with >30%. µ denotes the true log-odds 
ratio, φ the true correlation in each scenario and σu the standard deviation of the log-odds of the average 
risk. Large heterogeneity in average risk corresponds to σu > 2. Gain in precision corresponds to the 
percentage reduction in the width of the 95% CrI, of our model vs. the beta-binomial. MSE:mean squared 
error.  
 
  Bivariate binomial bivariate beta-binomial  
# 
Scenario description 
Mean 
bias 
MSE 
Cove
rage 
Power 
Mean 
bias 
MSE 
Cove
rage 
Power 
Precision 
gained 
µ = 0 
1 
φ
 =
 0
.3
 No SZ/DZ 0.012 0.024 95% - 0.002 0.018 99% - 29% 
2 Some SZ/DZ 0.006 0.044 96% - 0.000 0.030 100% - 30% 
3 Many SZ/DZ 0.031 0.059 96% - 0.017 0.055 98% - 29% 
4 
φ
 =
 0
.6
 No SZ/DZ 0.000 0.022 98% - 0.007 0.010 100% - 27% 
5 Some SZ/DZ 0.006 0.032 95% - 0.008 0.029 99% - 41% 
6 Many SZ/DZ 0.002 0.031 95% - 0.004 0.024 99% - 38% 
µ = 0.5 
7 
φ
 =
 0
.3
 
No SZ/DZ 0.017 0.024 96% 90% 0.043 0.013 98% 53% 31% 
 Some SZ/DZ and:     
0.042 0.056 100% 16% 
 
8 Informative priors 0.022 0.054 95% 69% 39% 
9 Vague priors 0.037 0.069 97% 56% 22% 
10 Misspecified priors 0.014 0.050 97% 59% 36% 
11 Many SZ/DZ 0.026 0.079 91% 59% 0.005 0.077 97% 13% 34% 
12 
φ
 =
 0
.6
 
No SZ/DZ 0.006 0.016 98% 90% 0.052 0.015 100% 49% 43% 
 Some SZ/DZ and:     
0.040 0.047 98% 12% 
 
13 Informative priors 0.008 0.054 95% 82% 44% 
14 Vague priors 0.035 0.062 97% 75% 32% 
15 Misspecified priors 0.017 0.048 98% 67% 33% 
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16 Many SZ/DZ 0.076 0.066 91% 71% 0.033 0.064 99% 17% 43% 
µ=0.5. Assumed large σu (variability in the average risk) 
17 φ=0.3 Many SZ/DZ 0.000 0.063 97% 44% 0.258 0.103 81% 1% 18% 
18 φ=0.3 Some SZ/DZ 0.024 0.028 98% 77% 0.221 0.071 95% 1% 39% 
19 φ=0.6 Many SZ/DZ 0.040 0.071 96% 60% 0.242 0.112 86% 2% 29% 
20 φ=0.0 Many SZ/DZ 0.011 0.046 100% 45% 0.260 0.101 87% 0% 25% 
 
Table 4: Results from analysing scenarios 21 and 22, for different choices of priors for the model 
parameters. µ denotes the log-odds ratio and φ the correlation. µu and σu denote the mean and standard 
deviation of the average risk. 
# Scenario 
Informative 
priors used for 
Mean 
bias 
MSE Coverage Power 
Increase in precision 
compared to non-
informative priors 
21 
µ=0.5, φ=0.3 
Many SZ/DZ 
– 0.067 0.250 94% 25% (reference) 
τ
2 0.016 0.210 90% 41% 30% 
φ 0.055 0.227 97% 21% 0% 
µu and σu 0.056 0.227 95% 27% 5% 
22 
µ=0.5, φ=0.6 
Many SZ/DZ 
– 0.094 0.146 96% 25% (reference) 
τ
2 0.046 0.114 90% 55% 29% 
φ 0.078 0.132 98% 21% 0% 
µu and σu 0.068 0.124 96% 26% 5% 
 
 
Page 36 of 68
https://mc.manuscriptcentral.com/smmr
Statistical Methods in Medical Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Three possible configurations of the 2x2 table of a study of 100 bilateral interventions reporting only the 
margins of the contingency table. The first configuration corresponds to a large positive correlation 
(φ=0.80), the second to no correlation (φ=0), the third to a large negative correlation (φ=-0.53).  
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Graphical analysis of the different ways in which the observed events can be distributed among different 
categories of patients in a mixed-design study. x, y and n1 are not reported.  
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Meta-analysis for minor events, endoscopic vs. open surgical operation for CTS, using a range of alternative 
models: UNI-FE (B/F): univariate fixed-effect (Bayesian/Frequentist), UNI-RE (B/F): univariate random-
effects (Bayesian/Frequentist), BB-FE: bivariate binomial fixed-effect (Bayesian), BB-RE: bivariate binomial 
random-effects (Bayesian). For all Bayesian models we present the median of the posterior distribution.  
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Meta-analysis for uncorrected visual acuity (UCVA) of 20/20 or better, at six months after treatment, LASIK 
vs. PRK for myopia. Model abbreviations as per Figure 3.  
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Appendix for “A model for meta-analysis of 
correlated binary outcomes: the case of split-
body interventions” 
 
1 Description of the data 
1.1 CTS example 
The available data is summarized in Table 1, and is also presented in the following 
forestplot. Note that for illustration purposes DZ studies are not shown in the graph and that 
for SZ studies we used a continuity correction. 
Table 1: Available data for the CTS example. re (ro) denotes events in endoscopic (open) 
surgical operation for CTS. Ne (No) denotes total number of patients in each arm.  
Study  
ID 
Study   
design 
      (patients) 
1 Unilateral 5 63 8 63 126 
2 Unilateral 5 23 8 22 45 
3 Unilateral 6 44 2 35 79 
4 Unilateral 0 128 2 60 188 
5 Unilateral 0 99 0 77 176 
6 Unilateral 0 85 0 91 176 
7 Unilateral 2 30 16 31 61 
8 Unilateral 2 74 3 76 150 
9 Unilateral 0 47 0 54 101 
10 Unilateral 1 24 0 24 48 
11 Unilateral 2 46 0 44 90 
12 Unilateral 3 45 3 35 80 
13 Bilateral 1 25 2 25 25 
14 Bilateral 3 60 3 60 60 
15 Bilateral 2 20 6 20 20 
16 Mixed 2 82 3 65 122 
17 Mixed 4 84 12 85 126 
18 Mixed 3 53 21 52 71 
19 Mixed 3 16 1 16 29 
20 Mixed 0 8 0 9 16 
21 Mixed 12 34 23 36 62 
22 Mixed 0 97 0 95 147 
23 Unknown 1 32 0 36 . 
24 Unknown 1 50 0 50 . 
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1.2 Myopia example 
The available data for this example is summarized in Table 2, also shown in the 
following forest plot.  
Table 2: Available data for the myopia example. rL (rP) denotes events in LASIK (PRK) 
operation for myopia. NL (NP) denotes total number of patients in each arm. 
Study  
ID 
Study   
type 
      (patients) 
1 Unilateral 1 25 3 20 45 
2 Unilateral 16 61 13 68 129 
3 Bilateral 46 50 47 50 50 
4 Bilateral 19 28 12 28 28 
5 Bilateral 23 25 24 25 25 
6 Bilateral 30 33 32 33 33 
7 Bilateral 43 44 42 44 44 
8 Unknown 8 8 8 9 - 
9 Unknown 43 57 46 61 - 
10 Unknown 89 109 240 335 - 
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2 Details for the model used for analysing bilateral studies that 
do not provide cross-classifications 
Assume a bilateral study , providing data for the number of events in each 
treatment (	, and ,) and the number of patients, . Let us denote by 	, the 
probability of having an event in treatment A; likewise for B. The corresponding 
likelihood is as follows: 
 =  !,! 	, − ,! , − ,!  − 	, − , + ,!		
	(, ,!, )
#$, %&'	((,, )!, *+ )	
 
× ,#$, -,, *#$, .,!, *#$/,+ *, *!, )#$,  
, = 	, 	, + 01	,1 − 	,,(1 − ,) 
 -, = 	, − ,  
., = , − , 
/, = 1 − , − -, − ., 
3456	, = 7 + 82  
 3456, = 7 − : -  
7~(<=, >=-) 
8~(<, ?-) 
<=, <, ?, >=, 0~…	(4	AB6C764B) 
The likelihood includes 3 independent parameters per study ,, -,, ., (/, can be 
calculated given these 3), but only 2 observed proportions are in the data (i.e. 
, 
+ , 
!, 
+ ). 
Including prior distributions for the 3 parameters would lead to identifiability issues. 
Instead, we add to the model external information regarding 0, the 3 model parameters 
are mapped into 	,, , and 0, rendering the model identifiable.  
In this expression:  
• , denotes the (unknown) number of patients having an event in both 
treatments. 
• , denotes the probability of having an event in both treatments.  
• -, denotes the probability of having an event in treatment A but not treatment 
B.  
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• ., denotes the probability of having an event in treatment B but not treatment 
A.  
• /, denotes the probability of having no events in either treatment. 
• <= denotes the mean log-odds of the average risk, and >=- the corresponding 
variance. 
• ?- denotes the variance of random effects. 
• 0 denotes the correlation. 
• 8 denotes the study-specific true treatment effects 
• <	denotes the true underlying log-odds ratio  
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3 Alternative method for reconstructing the 2x2 table 
In Section 3.3 of the main paper we discuss how researchers can stochastically reconstruct 
the 2x2 table (Table 2 in main paper) using the margins of the table and a prior distribution for the 
0 coefficient. Here we describe an alternative parameterization, which is based on the odds ratio of 
the cross-classified information.   
We start by defining DEFF = G$GHGIGJ. By virtue of Equation 4 in the main paper, we can see that  
KEFF > 1 corresponds to a positive correlation; KEFF < 1 corresponds to negative correlation; 
KEFF = 1 corresponds to zero correlation. Thus KEFF 	can serve as an alternative measure of 
correlation. 
We have 	 =  + -,  =  + . and  + - + . + / = 1. Thus, given KEFF and the 
margins (	 and ) we can solve the system of equations to obtain , -, . and /. The solution 
for  is the following: 
 = − N2(1 − KEFF) ±
PN- + 4	KEFF(1 − KEFF)	
2(1 − KEFF)  
where 
N = 1 − (1 − KE)(	 + ) 
The advantage of this method, as compared with the method based on 0, is that DEFF ranges 
from 0 to +∞, i.e. it is not bounded like 0. The disadvantage is that it is much more difficult to 
decide or elicit clinically meaningful values for KEFF. Thus, we do not consider this approach any 
more in this paper.  
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4 Details for the model used for analysing mixed design studies 
that do not provide cross-classifications 
Assume a study , which included a mixture of unilateral and bilateral interventions, 
and which provided information on the events in each treatment group (	,, ,), the total 
number of patients receiving each treatment (	,, ,), and the total number of patients 
in the study (). The corresponding likelihood is as follows: 
 =  		  S	,
=
T U 	,
V 1 − 	,+, 
W *V 	
+!, W ,!, 
X %&'(,!, 	*+ Y
	(#, W ,, )
V %&'(,, *+ Y
× S,=Z U ,
X 1 − ,+!, 
W *X 
 
× S,=Z U ,
X 1 − ,+!, 
W *X  
[!
,! 	, − T − ,!		
	(, *V ,!, *X )
#$, %&'	((,, *V )!, *X *+ Y)	
 
× 1, − Z − ,! [ − 	, − , + T + Z + ,! 
× ,#$, 	-,, *V *#$, 	.,!, *X *#$. 	/,+ 
Y*, *!, )V )X )#$, 
 
, = 	, 	, + 01	,1 − 	,,(1 − ,) 
 -, = 	, − ,  
., = , − , 
/, = 1 − , − -, − ., 
3456	, = 7 + 82  
 3456, = 7 − : -  
7~(<=, >=-) 
8~(<, ?-) 
<=, <, ?, >=, 0~…	(4	AB6C764B) 
In this expression:  
• 	,= 	denotes the number of unilateral patients receiving A. It is equal to 
	,= =  − ,. 
• ,= 	denotes the number of unilateral patients receiving B. It is equal to 
,= =  − 	,. 
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• [ denotes the number of bilateral patients. It is equal to [ = 	, + , −
 . 
• T denotes the (unknown) number of events in treatment A that were observed 
in the unilateral patients. It holds that max0, 	 − [ < T < min	(	,= , 	,) 
• Z denotes the (unknown) number of events in treatment B that were observed 
in the unilateral patients. It holds that max0,  − [ < Z < min	(,= , ,) 
The rest of the parameters are as described in the previous Section of this 
Appendix.  
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5 Summary table on how to choose the correct likelihood 
 
Table 3: Choosing the correct likelihood in each study depending on its design and the 
availability of cross-classified information. 
Study design 
All cross-classified information is 
available 
cross classified information is not 
available 
unilateral 
Use two univariate binomial 
distributions 
(not applicable) 
bilateral 
Use a multinomial likelihood 
(equation 5 in paper) 
Use a bivariate binomial likelihood 
(equation 6 in paper) with external 
information for φ 
mixed 
• Use two independent univariate 
binomial distributions for patients 
receiving unilateral interventions 
• Use a multinomial likelihood for 
patients receiving bilateral 
interventions (equation 5 in paper) 
Extended bivariate binomial 
distribution (equation 7 in paper) 
with external information for φ 
 
unknown (not applicable)  
If correlation is expected to be 
positive and we are interested in the 
most conservative estimate, treat as 
unilateral 
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6 Eliciting prior distributions for the average risk 
Here we discuss a method for eliciting expert opinion regarding the average risk. We 
also discuss how to combine opinions from different experts to formulate a prior 
distribution, possibly after weighting each expert’s opinion. The methods has been 
described in [1, 2].  
We ask c experts the following question: 
 
“A total of N patients were randomized to receive treatment A or B for the target 
condition (<specify treatments and condition>). What percentage of them do you expect to 
have a positive outcome (<specify outcome>)? Please provide a 95% confidence interval 
for this proportion.” 
 
The d-th expert (d = 1, . . , c) provides an estimate for the 95% confidence interval 
for the baseline risk. Let us denote the average risk [. Assuming the expert’s opinion to 
come from a beta distribution we can construct a prior ef([) = gh6i([; if , Cf) from the 
provided confidence interval. In [2] we had provided an R code for calculating the 
parameters if and Cf (freely available online at  
http://www.mtm.uoi.gr/images/BetaPriors%20for%20MONMA.txt.txt). 
After calculating the individual if and Cf for each expert d, an overall prior can be 
obtained as a combination of the individual expert opinions: 
k([) ∝ (e([))m$(e-([))mI …(e+n([))mon =p(ef([))mq
f
 (1) 
The rf parameters are weights (∑ rf = 1)+nf%  that are assigned to experts. These can 
be chosen to reflect the credibility attached to each expert opinion. For example, we can 
define the weights based on the years of relevant clinical experience of each expert.  
Equation (1) suggests that the prior distribution for [ is a beta distribution 
[~gh6i(∑rfif , ∑rfCf). This can be used as a prior distribution for average risk.  
In order to use this formulation, the model described in the paper (and also in the 
previous paragraph of this appendix) needs to be slightly changed: 
3456	, = 3456([,) + 82  
 3456, = 3456([,) − : -  
[,~gh6i trfif ,rfCfu 
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7 Eliciting prior distributions for the φ coefficient 
(correlations) 
We ask c medical experts the following question: 
 
 “A number of patients received both A and B treatments (<specify treatments and 
condition>). We measure the number of events for a specific outcome (<specify outcome>). 
Some of the patients had an event only in A, some only in B, some in both treatments, and 
some in neither treatments. 
We want to explore the relationship between having an event in one of the treatments 
with having an event in the other. For example, patients that experience an event in A may 
be more prone to have an event in B as well. Or, conversely, it might be the case that 
patients who had an event in A are less likely to have an event in B. 
We want to quantify this relationship (correlation) using a measure ranging from -1 to 
+1. A correlation equal to -1 indicates a perfectly negative relationship between the two 
events, i.e. if a patient had an event in A he/she will not have the event in B. 
A correlation equal to +1 indicates a perfect positive correlation, i.e. an event A 
guarantees an event in B. 
A correlation of 0 means that the two events are completely independent, i.e. the 
probability of a patient having an event in A does not depend on whether or not he/she had 
an event in B. 
Can you provide a range of values in which you are 95% certain that the true value of 
this correlation lies? Please provide values for 0vwmx and 0=GGx, as described in the 
picture below.” 
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We use the Fisher transformation, y = - log t})*}u to transform the elicited values for 
0 into the (−∞,+∞), in order to construct a normal prior. Using the Fisher-transformed 
lower and upper values of the correlation (yvwmx and y=GGx) we can calculate y~x# =
(y=GGx + yvwmx)/2 and > = (y=GGx − yvwmx)/3.92. 
Having calculated a y~x#,f and a >,f-  from each expert d, we can combine all 
information by performing an inverse variance meta-analysis, where the input of each 
expert (y~x#,f) is weighted according to the certainty this expert places on the 
corresponding estimate (as quantified by >,f- ). In order to further weight expert opinions 
e.g. according to their experience, we can substitute the variance by 
,qI
mq  [3]. Here rf 
measures the experience of expert d, e.g. it can be taken to be equal to the years of 
experience in the field, or the number of RCTs in which this expert has been involved in.  
Using the outcome of this meta-analysis (pooled estimate and standard error) we can 
formulate a distribution for y, to use in a Bayesian setting as a prior.  
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8 R code for generating the data used in the simulations 
For each scenario we generate 100 meta-analyses, for each meta-analysis we generate 20 
studies. For the d-th meta-analysis we start by defining <f , <=,f, >=,f, 0f .	We draw 
?-~LN(−2, 1.5). The parameters of this distribution were chosen to approximate empirical 
distributions described in [4].  For study  in meta-analysis d we generate 8,f~	(<f , ?f-), 
7,f~(<=,f, >=,f- ). We generate the number of patients in each study, ,f by drawing from 
a uniform distribution, U(50,100).  
library(MASS) 
Nstudies<- 20 
Nmeta=100 
mu=0.5 
phi=0.6 
tau.s=rlnorm(Nmeta, meanlog = -2, sdlog = 1.5) 
Np=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
for (k in 1:Nmeta){  
  for (j in 1:Nstudies){ 
    Np[k,j]=round(runif(1,50,100))}} #simulate number of patients 
 
data4=array(rep(0,Nstudies*Nmeta*8), dim=c(Nmeta,Nstudies,20)) 
for (k in 1:Nmeta){ 
  Sigma <- matrix(c(tau.s[k],0,0,1),2,2) 
  aaa=mvrnorm(n =Nstudies, c(mu,-3), Sigma) 
 
  for (j in 1:Nstudies){ 
        data4[k,j,1]=aaa[j,1]#logor: logit(pA)-logit(pB) 
        data4[k,j,2]=aaa[j,2] #####u: logit(pA)+logit(pB)/2 
        data4[k,j,3]=-data4[k,j,1]/2+data4[k,j,2] ###logit(pA) 
        data4[k,j,4]=+data4[k,j,1]/2+data4[k,j,2]  ###logit(pB) 
     }} 
   
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
    data4[k,j,3]=exp(data4[k,j,3])/(1+exp(data4[k,j,3]))#####pA 
  }} 
 
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
    data4[k,j,4]=exp(data4[k,j,4])/(1+exp(data4[k,j,4])) #####pB 
  }} 
 
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
    data4[k,j,20]=max(data4[k,j,3],data4[k,j,4])####pimin 
    data4[k,j,19]=min(data4[k,j,3],data4[k,j,4])###pimax 
    data4[k,j,18]=sqrt(data4[k,j,19]*(1-data4[k,j,20])/(data4[k,j,20]*(1-
data4[k,j,19])))###phimax 
      data4[k,j,16]=max(0,data4[k,j,3]+data4[k,j,4]-1)###test 
  }} 
 
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
    data4[k,j,17]=( 
      (data4[k,j,16]*(1-data4[k,j,3]-data4[k,j,4]+data4[k,j,16])-
(data4[k,j,3]-data4[k,j,16])*(data4[k,j,4]-data4[k,j,16])) 
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      / 
        sqrt(data4[k,j,3]*data4[k,j,4]*(1-data4[k,j,3])*(1-data4[k,j,4])) 
      ) 
    
data4[k,j,5]=max(0.0000001,data4[k,j,3]*data4[k,j,4]+min(max(phi,data4[k,
j,17]),data4[k,j,18])*sqrt(data4[k,j,3]*data4[k,j,4]*(1-data4[k,j,3])*(1-
data4[k,j,4]))) 
data4[k,j,6]=max(0.0000001,data4[k,j,3]-data4[k,j,5]) 
data4[k,j,7]=max(0.0000001,data4[k,j,4]-data4[k,j,5]) 
data4[k,j,8]=1-data4[k,j,5]-data4[k,j,6]-data4[k,j,7] 
  }} 
 
aa2=array(rep(0,Nmeta*4*Nstudies), dim=c(Nmeta,Nstudies,4)) 
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
    aa2[k,j,1:4]=rmultinom(1,Np[k,j],data4[k,j,5:8]) 
  }} 
 
n11=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
n12=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
n13=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
n14=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
 
 
for (k in 1:Nmeta){ 
  for (j in 1:Nstudies){ 
n11[k,j]=aa2[k,j,1] 
n12[k,j]=aa2[k,j,2] 
n13[k,j]=aa2[k,j,3] 
n14[k,j]=aa2[k,j,4] 
}} 
 
nA=n11+n12 
nB=n11+n13 
Np=n11+n12+n13+n14 
 
lower=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
range1=array(rep(0,Nmeta*Nstudies), dim=c(Nmeta,Nstudies)) 
 
for (k in 1:Nmeta){  
  for (j in 1:Nstudies){ 
    lower[k,j]=max(0,nA[k,j]+nB[k,j]-Np[k,j])}} 
 
for (k in 1:Nmeta){  
  for (j in 1:Nstudies){ 
    range1[k,j]=1+min(nA[k,j],nB[k,j])-max(0,nA[k,j]+nB[k,j]-Np[k,j])}} 
 
sum(nA[,]) 
sum(nB[,]) 
 
 
dput(Nstudies) 
dput(nA) 
dput(nB) 
dput(Np) 
dput(lower) 
dput(range1) 
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9 OpenBUGS code for analysing the simulated datasets 
Data needed: Nmeta (number of meta-analyses), NS (number of studies), r.e.II 
(events in treatment A), r.o.II (events in treatment B), Npatients.II (#patients per study), 
lower.II (equal to max(0,r.e.II+r.o.II-Npatients.II)), range.II (equal to 1+min(r.e.II, r.o.II)-
max(0,r.e.II+r.o.II-Npatients). All inputs except Nmeta and NS are data structures of 
dimensions NSxNmeta. 
model{ 
for (i in (1):(Nmeta)){  
for (k in (1):(NS)){  
pmax[k,i]<-max(p.e[k,i],p.o[k,i]) 
pmin[k,i]<-min(p.e[k,i],p.o[k,i]) 
phimax[k,i]<-sqrt(pmin[k,i]*(1-pmax[k,i])/(pmax[k,i]*(1-pmin[k,i])))   
# study-specific max value for phi 
fisher.phimax[k,i]<-1/2*log((1+phimax[k,i])/(1-phimax[k,i])) 
test[k,i]<-max(0,p.e[k,i]+p.o[k,i]-1) 
phimin[k,i]<-((test[k,i]*(1-p.e[k,i]-p.o[k,i]+test[k,i])-(p.e[k,i]-
test[k,i])*(p.o[k,i]-test[k,i])) 
/sqrt(p.e[k,i]*p.o[k,i]*(1-p.e[k,i])*(1-p.o[k,i]))) 
fisher.phimin[k,i]<-1/2*log((1+phimin[k,i])/(1-phimin[k,i]))}} 
# the elicited distribution for Fisher-transformed phi is truncated to a 
study-specific range of allowed values 
for (i in (1):(Nmeta)){  
for (k in (1):(NS)){  
    Fphi.study1[k,i]~ dunif(0,1) 
 Fphi.study2[k,i] <-min(Fphi.study1[k,i] ,fisher.phimax[k,i]) 
Fphi.study[k,i] <-max(Fphi.study2[k,i],phimin[k,i]) 
}} 
# the 2x2 table is reconstructed 
for (i in (1):(Nmeta)){  
for (k in (1):(NS)){  
phi.study[k,i]<-tanh(Fphi.study[k,i]) 
p[k,i,1]<-p.e[k,i]*p.o[k,i]+phi.study[k,i]*sqrt(p.e[k,i]*p.o[k,i]*(1-
p.e[k,i])*(1-p.o[k,i])) 
p[k,i,2]<-p.e[k,i]-p[k,i,1] 
p[k,i,3]<-p.o[k,i]-p[k,i,1] 
p[k,i,4]<-1-p[k,i,1]-p[k,i,2]-p[k,i,3] 
}} 
# likelihood of the observations 
for (i in (1):(Nmeta)){  
for (m in (1):(NS)){  
dummy[m,i]<- 0  # dummy variable 
dummy[m,i] ~ dloglik(logLike.II[m,i])  # likelihood is exp(logLike.II[i]) 
for (k in 1:range.II[m,i]) {n11[m,i,k]<-lower.II[m,i]+k-1} 
for (k in 1:range.II[m,i]) { 
loglike.II[m,i,k]<- 
(logfact(Npatients.II[m,i])) 
+log(max(0.000001,p[m,i,2]))*(r.e.II[m,i]-n11[m,i,k])  
+log(max(0.000001,p[m,i,3]))*(r.o.II[m,i]-n11[m,i,k]) 
+log(max(0.000001,p[m,i,1]))*(n11[m,i,k]) 
+log(max(0.000001,p[m,i,4]))*(Npatients.II[m,i]-r.e.II[m,i]-
r.o.II[m,i]+n11[m,i,k]) 
-( 
(logfact(n11[m,i,k])) 
+(logfact((r.e.II[m,i]-n11[m,i,k]))) 
+(logfact((r.o.II[m,i]-n11[m,i,k]))) 
+(logfact((Npatients.II[m,i]-r.e.II[m,i]-r.o.II[m,i]+n11[m,i,k]))) 
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) 
like[m,i,k]<-exp(loglike.II[m,i,k])} 
A1[m,i]<-max(0,sum(like[m,i,1:range.II[m,i]])) 
logLike.II[m,i]<-log(A1[m,i])}} 
##prior distributions and parameterizing  
for (i in (1):(Nmeta)){  
for (k in 1:(NS)){ 
  logit(p.e[k,i]) <- theta[k,i,1]-theta[k,i,2]/2 
  logit(p.o[k,i]) <- theta[k,i,1]+theta[k,i,2]/2 
  theta[k,i,1:2] ~dmnorm(m1[i,1:2],prectau[i,1:2,1:2]) 
  } 
 
 m1[i,1]<-aa[i] 
 m1[i,2]~dunif(-2,4) 
  ss[i,1,1]<-(bb[i]*bb[i]) 
  ss[i,1,2]<-0 
 ss[i,2,1]<-0 
 ss[i,2,2]<-tau.s[i] 
 prectau[i,1:2,1:2]<-inverse(ss[i,1:2,1:2]) 
tau.s[i]~dunif(0,5) 
aa[i]~dunif(-10,10) 
bb[i]~dunif(0,5)}}}}}} 
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10 Simulations  
10.1 Scenarios 1-20 
Here we provide a description of scenarios 1-20.  In the following table φ is the correlation coefficient assumed in each scenario, and y is 
the Fisher transformation of 0.  % SZ (%DZ) shows the percent of single-zero (double-zero) studies in each scenario. <= and >= denote the 
mean and the variance of the average log-odds of event in the studies. For each scenario we simulated 100 meta-analyses. Each meta-analysis 
included 20 studies. Each study had 50-100 simulated patients  
 
Table 4: Detailed description of the explored scenarios and of the priors used in the analyses, scenarios 1-20 
 Description of the simulated datasets Priors used in the analyses 
Scenario 
# 
Scenario description ζ µu σu 
% SZ 
(% DZ) 
µ ζ µu σu τ
2 µ 
1 
Zero relative effects 
 Low correlation 
No SZ and DZ studies 
0.31 -1.5 0.5 
0.2% 
(0.0%) 
0.0 N(0.3,0.12) U(-4,0) U(0,3) LN(-2,1.52) U(-2,2) 
2 
Zero relative effects 
Low correlation,  
Some SZ and DZ studies 
0.31 -3.5 1.0 
20% 
(10%) 
0.0 N(0.3,0.1
2
) U(-5,-1) U(0,3) LN(-2,1.5
2
) U(-2,2) 
3 
Zero relative effects 
Low correlation,  
Many SZ and DZ studies 
0.31 -4.0 1.0 
25% 
(19%) 
0.0 N(0.3,0.1
2
) U(-6,-1) U(0,3) LN(-2,1.5
2
) U(-2,2) 
4 
Zero relative effects 
Large correlation 
No SZ and DZ studies 
0.69 -1.5 0.5 
0.9% 
(0.2%) 
0.0 N(0.7,0.22) U(-4,0) U(0,3) LN(-2,1.52) U(-2,2) 
5 
Zero relative effects 
Large correlation  
Some SZ and DZ studies 
0.69 -3.5 1.0 
14% 
(14%) 
0.0 N(0.7,0.22) U(-5,-1) U(0,3) LN(-2,1.52) U(-2,2) 
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6 
Zero relative effects 
Large correlation 
Many SZ and DZ studies 
0.69 -4.0 1.0 
15% 
(20%) 
0.0 N(0.7,0.2
2
) U(-6,-1) U(0,3) LN(-2,1.5
2
) U(-2,2) 
7 
Non-zero relative effects 
Low correlation 
No SZ and DZ studies 
0.31 -1.5 0.5 
0.8% 
(0.1%) 
0.5 N(0.3,0.12) U(-4,0) U(0,3) LN(-2,1.52) U(-2,2) 
8 
Non-zero relative effects 
Low correlation,  
Some SZ and DZ studies 
0.31 -3.5 1.0 
21% 
(9%) 
0.5 
N(0.3,0.12) U(-5,-1) U(0,3) LN(-2,1.52) U(-2,2) 
9 
Non-zero relative effects 
 Low correlation 
Some SZ and DZ studies 
Vague priors 
U(0,10) U(-10,10) U(0,5) U(0,5) U(-10,10) 
10 
Non-zero relative effects 
 Low correlation 
Some SZ and DZ studies 
Misspecified priors 
U(0.5,1) U(-3,0) U(0,2) U(0,5) U(-5,5) 
11 
Non-zero relative effects 
Low correlation,  
Many SZ and DZ studies 
0.31 -4.0 1.0 
28% 
(18%) 
0.5 N(0.3,0.1
2
) U(-6,-1) U(0,3) LN(-2,1.5
2
) U(-2,2) 
12 
Non-zero relative effects 
Large correlation 
No SZ and DZ studies 
0.69 -1.5 0.5 
0.8% 
(0.1%) 
0.5 N(0.7,0.2
2
) U(-4,0) U(0,3) LN(-2,1.5
2
) U(-2,2) 
13 
Non-zero relative effects 
Large correlation  
Some SZ and DZ studies 
0.69 -3.5 1.0 
18% 
(12%) 
0.5 
N(0.7,0.22) U(-5,-1) U(0,3) LN(-2,1.52) U(-2,2) 
14 
Non-zero relative effects 
 Large correlation 
Some SZ and DZ studies 
Vague priors 
U(0,10) U(-10,10) U(0,5) U(0,5) U(-10,10) 
15 
Non-zero relative effects 
 Large correlation 
U(0,0.5) U(-3,0) U(0,2) U(0,5) U(-5,5) 
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Some SZ and DZ studies 
Misspecified priors 
16 
Non-zero relative effects 
Large correlation 
Many SZ and DZ studies 
0.69 -4.0 1.0 
23% 
(22%) 
0.5 N(0.7,0.2
2
) U(-6,-1) U(0,3) LN(-2,1.5
2
) U(-2,2) 
17 
Non-zero relative effects 
 Low correlation 
Many SZ and DZ studies 
Vague priors 
Large heterogeneity in 
baseline risk 
0.31 -3.0 3.0 
21% 
(21%) 
0.5 U(0,0.5) U(-5,5) U(0,5) U(0,5) U(-5,5) 
18 
Non-zero relative effects 
 Low correlation 
Some SZ and DZ studies 
Vague priors 
Large heterogeneity in 
baseline risk 
0.31 -2.0 2.0 
6% 
(22%) 
0.5 U(0,10) U(-5,5) U(0,5) U(0,5) U(-5,5) 
19 
Non-zero relative effects 
 Large correlation 
Many SZ and DZ studies 
Vague priors 
Large heterogeneity in 
baseline risk 
0.69 -3.0 3.0 
14% 
(24%) 
0.5 U(0,10) U(-5,5) U(0,5) U(0,5) U(-5,5) 
20 
Non-zero relative effects 
 Zero correlation 
Some SZ and DZ studies 
Vague priors 
Large heterogeneity in 
baseline risk 
0.00 -3.0 3.0 
18% 
(12%) 
0.5 U(0,10) U(-5,5) U(0,5) U(0,5) U(-5,5) 
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10.2 Scenarios 21 and 22 
 
In the following table we present an overview of scenarios 21-22 and the priors used in their analyses. 
 
Table 5: Detailed description of the scenarios 21 and 22, and of the priors used in their analyses 
 
 Description of the simulated datasets 
Scenario 
# 
Scenario description ζ µu σu 
% SZ 
(% DZ) 
µ ζ µu σu τ
2 
21 
Non-zero relative effects 
Low correlation 
Many SZ and DZ studies 
10 studies per meta-analysis 
0.31 -3.0 1.0 
25% 
(14%) 
0.5 
U(0,10) U(-10,10) U(0,5) U(0,5) 
U(0,10) U(-10,10) U(0,5) LN(-2,1.52) 
N(0.3,0.12) U(-10,10) U(0,5) U(0,5) 
U(0,10) U(-4,2) U(0,2) U(0,5) 
22 
Non-zero relative effects 
Large correlation 
Many SZ and DZ studies 
10 studies per meta-analysis 
0.69 -3.0 1.0 
20% 
(17.6%) 
0.5 
U(0,10) U(-10,10) U(0,5) U(0,5) 
U(0,10) U(-10,10) U(0,5) LN(-2,1.5
2
) 
N(0.7,0.12) U(-10,10) U(0,5) U(0,5) 
U(0,10) U(-4,2) U(0,2) U(0,5) 
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11 OpenBUGS code used for the analysis of real data-sets 
Here we provide the OpenBUGS code as well as the data used for the analysis of the CTS 
example.  
model{ 
### two interventions, endoscopic (e) and open (o) for CTS 
 
######################################## 
#####  UNILATERAL STUDIES  ###### 
######################################## 
#likelihood in each study i 
for (i in 1:NS1){ 
r.e.I[i]~dbin(p.e[i],N.e.I[i]) 
r.o.I[i]~dbin(p.o[i],N.o.I[i])} 
######################################## 
 
 
######################################## 
# parameters of normal prior distribution for the Fisher-
transformed correlation coefficient (y), needed for bilateral 
and mixed studies 
m.fisherphi<-0.2 # mean  
sigma.fisherphi<-0.1 # standard deviation 
prec.fisherphi<-1/(sigma.fisherphi*sigma.fisherphi)# precision 
 
# study specific max-min values for phi  
for (i in (NS1+1):(NS1+NS2+NS3)){  
pmax[i]<-max(p.e[i],p.o[i]) 
pmin[i]<-min(p.e[i],p.o[i]) 
phimax[i]<-sqrt(pmin[i]*(1-pmax[i])/(pmax[i]*(1-pmin[i]))) 
fisher.phimax[i]<-1/2*log((1+phimax[i])/(1-phimax[i])) 
test[i]<-max(0,p.e[i]+p.o[i]-1) 
phimin[i]<-((test[i]*(1-p.e[i]-p.o[i]+test[i])-(p.e[i]-
test[i])*(p.o[i]-test[i])) 
/sqrt(p.e[i]*p.o[i]*(1-p.e[i])*(1-p.o[i]))) 
fisher.phimin[i]<-1/2*log((1+phimin[i])/(1-phimin[i]))} 
 
# the elicited distribution for Fisher-transformed phi is 
truncated to the study-specific range of allowed values 
for (i in (NS1+1):(NS1+NS2+NS3)){  
        Fphi.study1[i] ~ dnorm(m.fisherphi,prec.fisherphi) 
 Fphi.study2[i] <-min(Fphi.study1[i] ,fisher.phimax[i]) 
Fphi.study[i] <-max(Fphi.study2[i], fisher.phimin[i]) 
} 
 
# probabilities of the 2x2 table are calculated 
for (i in (NS1+1):(NS1+NS2+NS3)){  
phi.study[i]<-tanh(Fphi.study[i]) 
p[i,1]<-p.e[i]*p.o[i]+phi.study[i]*sqrt(p.e[i]*p.o[i]*(1-
p.e[i])*(1-p.o[i])) 
p[i,2]<-p.e[i]-p[i,1] 
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p[i,3]<-p.o[i]-p[i,1] 
p[i,4]<-1-p[i,1]-p[i,2]-p[i,3]} 
 
 
######################################## 
#####  BILATERAL STUDIES  ###### 
######################################## 
 
# defining the likelihood of the observations 
for (i in (NS1+1):(NS1+NS2)){  
dummy[i]<- 0  # dummy variable 
dummy[i] ~ dloglik(logLike.II[i])  # likelihood is 
exp(logLike.II[i]) 
 
for (k in 1:range.II[i-NS1]) {n11[i,k]<-lower.II[i-NS1]+k-1} 
for (k in 1:range.II[i-NS1]) { 
loglike.II[i,k]<- 
(logfact(Npatients.II[i-NS1])) 
+log(max(0.000001,p[i,2]))*(r.e.II[i-NS1]-n11[i,k])  
+log(max(0.000001,p[i,3]))*(r.o.II[i-NS1]-n11[i,k]) 
+log(max(0.000001,p[i,1]))*(n11[i,k]) 
+log(max(0.000001,p[i,4]))*(Npatients.II[i-NS1]-r.e.II[i-NS1]-
r.o.II[i-NS1]+n11[i,k]) 
- 
( 
(logfact(n11[i,k])) 
+(logfact((r.e.II[i-NS1]-n11[i,k]))) 
+(logfact((r.o.II[i-NS1]-n11[i,k]))) 
+(logfact((Npatients.II[i-NS1]-r.e.II[i-NS1]-r.o.II[i-
NS1]+n11[i,k]))) 
) 
like[i,k]<-exp(loglike.II[i,k]) 
} 
A1[i]<-max(0,sum(like[i,1:range.II[i-NS1]])) 
logLike.II[i]<-log(A1[i])} 
 
######################################## 
#####  MIXED STUDIES  ###### 
######################################## 
for (ns in (NS1+NS2+1):(NS1+NS2+NS3)){ 
 
dummy[ns]<- 0 
dummy[ns] ~ dloglik(logLike.III[ns])    
 
 
for (i in lower.e.III[ns-NS1-NS2]:upper.e.III[ns-NS1-NS2]){ 
#the likelihood of each possible splitting of the endoscopic  
like_e[ns, i+1]<- 
pow(p.e[ns],i)* 
pow(1-p.e[ns],N.e.u.III[ns-NS1-NS2]-i) 
*exp(logfact(N.e.u.III[ns-NS1-NS2]))/ 
(exp(logfact(i))*exp(logfact(N.e.u.III[ns-NS1-NS2]-i)))} 
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for (i in  lower.o.III[ns-NS1-NS2]:upper.o.III[ns-NS1-NS2]){ 
#the likelihood of each possible splitting of the open  
like_o[ns, i+1]<-pow(p.o[ns],i)*pow(1-p.o[ns],N.o.u.III[ns-
NS1-NS2]-i)*exp(logfact(N.o.u.III[ns-NS1-
NS2]))/(exp(logfact(i))*exp(logfact(N.o.u.III[ns-NS1-NS2]-
i)))} 
 
for (i in (r.e.III[ns-NS1-NS2]-upper.e.III[ns-NS1-
NS2]):(r.e.III[ns-NS1-NS2]-lower.e.III[ns-NS1-NS2])){ 
##defining the part of the likelihood due to bilaterals   
for (j in (r.o.III[ns-NS1-NS2]-upper.o.III[ns-NS1-
NS2]):(r.o.III[ns-NS1-NS2]-lower.o.III[ns-NS1-NS2])){ 
for (k in 0:Ntest){ 
Test[ns,i+1,j+1,k+1]<- 
(exp(logfact( N.b.III[ns-NS1-NS2])) 
*pow(p[ns,2],i-k)  
*pow(p[ns,3],j-k) 
*pow(p[ns,1],k) 
*pow(p[ns,4], N.b.III[ns-NS1-NS2]-i-j+k) 
/ 
( 
exp(logfact(k)) 
*exp(logfact(i-k*step(min(i,j)-k))) 
*exp(logfact(j-k*step(min(i,j)-k))) 
*exp(logfact((N.b.III[ns-NS1-NS2]-i-j+k)*step(k-max(0,i+j-
N.b.III[ns-NS1-NS2])))) 
)) 
*step(k-max(0,i+j-N.b.III[ns-NS1-NS2])) 
*step(min(i,j)-k) 
 
likeBilateralsSub[ns,i+1,j+1,k+1]<-
Test[ns,i+1,j+1,k+1]*like_e[ns, r.e.III[ns-NS1-NS2]-
i+1]*like_o[ns, r.o.III[ns-NS1-NS2]-j+1] } 
test1[ns,i+1,j+1]<-
sum(likeBilateralsSub[ns,i+1,j+1,1:(Ntest+1)])} 
test2[ns,i+1]<-sum(test1[ns,i+1,(r.o.III[ns-NS1-NS2]-
upper.o.III[ns-NS1-NS2]+1):(r.o.III[ns-NS1-NS2]-
lower.o.III[ns-NS1-NS2]+1)])} 
test3[ns]<-max(0,sum(test2[ns, (r.e.III[ns-NS1-NS2]-
upper.e.III[ns-NS1-NS2]+1):(r.e.III[ns-NS1-NS2]-
lower.e.III[ns-NS1-NS2]+1)]))} 
 
for (ns in (NS1+NS2+1):(NS1+NS2+NS3)){ 
C1[ns]<-log(test3[ns]) 
logLike.III[ns]<- C1[ns]} 
 
 
##prior distributions, parameterizing  
for (i in 1:(NS1+NS2+NS3)){ 
  logit(p.e[i]) <- theta[i,1]-theta[i,2]/2 
  logit(p.o[i]) <- theta[i,1]+theta[i,2]/2 
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  theta[i,1:2] ~dmnorm(m1[1:2],prectau[1:2,1:2]) 
   
  
 } 
 m1[1]<-aa 
 m1[2]~dunif(-2,2) 
  ss[1,1]<-(bb*bb) 
  ss[1,2]<-0#r[i]*bb[i]*sqrt(tau.s[i]) 
 ss[2,1]<-0#r[i]*bb[i]*sqrt(tau.s[i]) 
 ss[2,2]<-tau.s 
  
prectau[1:2,1:2]<-inverse(ss[1:2,1:2]) 
 
 tau.s~dlnorm(-1.43,0.48) 
 #r[i]~dunif(-1,1) 
  
aa~dunif(-5,-1) 
bb~dunif(0,3) 
}}}}}} 
 
#### DATA for CTS 
list( 
NS1=14, NS2=3, NS3=7, ## number of studies in each design 
(unilateral, bilateral, mixed). 
 
###### data for unilateral studies 
r.e.I=c( 5, 5, 6, 0, 0, 0, 2, 2, 0, 1, 2, 3,1,1),## number of 
events in endoscopic, unilateral studies 
N.e.I=c(63,23,44,128,99,85,30,74,47,24,46,45,32,50), ## total 
number of patients in endoscopic, unilateral studies 
r.o.I=c( 8, 8, 2, 2, 0, 0,16, 3, 0, 0, 0, 3,0,0), ## number of 
events in open, unilateral studies, unilateral studies 
N.o.I=c(63,22,35,60,77,91,31,76,54,24,44,35,36,50), ## total 
number of patients in open, unilateral studies 
 
 
###### data for bilateral studies 
r.e.II=c( 1, 3, 2 ), ##  events endoscopic, bilateral studies 
r.o.II=c( 2, 3, 6),##  events open, bilateral studies 
Npatients.II=c(25,60,20), ## number of patients, bilateral 
studies 
lower.II=c(0,0,0), # this gives the starting value of n1 in 
the sum of equation 3 in the main paper. It is a vector equal 
to max(0,r.e.II+r.o.II-Npatients.II) for each study 
range.II=c(2,4,3), # this gives the number of possible values 
for n1 in the sum of equation 5 in the main paper. It is a 
vector equal to  
1+min(r.e.II,r.o.II)-max(0,r.e.II+r.o.II-Npatients.II) for 
each study 
 
 
###### data for mixed studies 
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r.e.III=c( 2, 4, 3, 3, 0,12, 0) ,## total events endoscopic, 
mixed studies 
r.o.III=c(  3,12,21, 1, 0,23, 0), ## total events open, 
mixedstudies 
N.b.III=c(25,43,34, 3, 1, 8,45), ## patients receiving 
bilateral interventions, mixed studies 
N.e.u.III=c(57,41,19,13, 7,26,52), ### patients unilateral, 
endoscopic, mixed studies 
N.o.u.III=c(40,42,18,13, 8,28,50),### patients unilateral, 
open, mixed studies 
Ntest=24, ## this is just an arbitrary large number. To 
facilitate convergence choose  
Ntest= max(r.e.III[i],r.o.III[i])+1,where i runs across all 
mixed studies.  
 
 
## boundaries for the number of events in unilateral 
interventions, for mixed studies  
##  ENDOSCOPIC 
lower.e.III=c(0,0,0,0,0,4,0),  ## this vector is equal to 
max(0,r.e.III-N.b.III) 
upper.e.III=c(2,4,3,3,0,12,0) ## this vector is equal to 
min(N.e.u.III,r.e.III) 
,  
##  OPEN 
lower.o.III=c(0,0,0,0,0,15,0), ## this vector is equal to 
max(0,r.o.III-N.b.III) 
upper.o.III=c(3,12,18,1,0,23,0) ## this vector is equal to 
min(N.o.u.III,r.o.III) 
 
 
) 
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12 R code used for the analysis of real data-sets 
Here we provide the R2WinBUGS code for fitting the model presented in this paper. The code 
provided in the previous section of this appendix needs to be saved in a txt file. The data correspond to 
the CTS example. 
library(R2WinBUGS) 
library(BRugs) 
 
 
NS1=14 
NS2=3 
NS3=7 
r.e.I=c( 5, 5, 6, 0, 0, 0, 2, 2, 0, 1, 2, 3,1,1) # number of events 
in endoscopic, unilateral studies 
N.e.I=c(63,23,44,128,99,85,30,74,47,24,46,45,32,50) ## total number 
of patients in endoscopic, unilateral studies 
r.o.I=c( 8, 8, 2, 2, 0, 0,16, 3, 0, 0, 0, 3,0,0) ## number of events 
in open, unilateral studies 
N.o.I=c(63,22,35,60,77,91,31,76,54,24,44,35,36,50)## total number of 
patients in open, unilateral studies 
r.e.II=c( 1, 3, 2 ) ##  events endoscopic, bilateral studies 
r.o.II=c( 2, 3, 6) ##  events open, bilateral studies 
Npatients.II=c(25,60,20) 
r.e.III=c( 2, 4, 3, 3, 0,12, 0) ## total events endoscopic, mixed 
studies 
r.o.III=c(  3,12,21, 1, 0,23, 0)## total events open, mixed studies 
 
N.b.III=c(25,43,34, 3, 1, 8,45) ## patients with bilateral 
interventions, mixed studies. This vector is equal to: Npatients(in 
endoscopic)+Npatients(open)-Npatients(all), see section 3.4 of the 
paper 
N.e.u.III=c(57,41,19,13, 7,26,52) ### patients unilateral 
endoscopic, mixed studies 
N.o.u.III=c(40,42,18,13, 8,28,50)### patients unilateral open, mixed 
studies 
 
Ntest=max(r.e.III[i],r.o.III[i])+1 ## this is just an arbitrary 
large number 
 
for(i in 
1:length(Npatients.II)){lower.II[i]=max(0,r.e.II[i]+r.o.II[i]-
Npatients.II[i])}  
for(i in 
1:length(Npatients.II)){range.II[i]=1+min(r.e.II[i],r.o.II[i])-
max(0,r.e.II[i]+r.o.II[i]-Npatients.II[i])} 
for(i in 1:length(Npatients.II)){lower.e.III[i]=max(0,r.e.III[i]-
N.b.III[i])} 
for(i in 
1:length(Npatients.II)){upper.e.III[i]=min(N.e.u.III[i],r.e.III[i])} 
for(i in 1:length(Npatients.II)){lower.o.III[i]=max(0,r.o.III[i]-
N.b.III[i])} 
for(i in 
1:length(Npatients.II)){upper.o.III[i]=min(N.o.u.III[i],r.o.III[i])} 
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data1<-list("NS1", "NS2", 
"NS3","r.e.I","N.e.I","r.o.I","N.o.I","r.e.II","r.o.II","Npatients.I
I","lower.II","range.II", 
            
"r.e.III","r.o.III","N.b.III","N.e.u.III","N.o.u.III","Ntest","lower
.e.III","upper.e.III","lower.o.III","upper.o.III") 
 
setwd("C:/…") # input working directory here 
bugs.data(data1, dir = getwd(), digits = 5, data.file = "data1.txt") 
 
parameters1=c("or","tau.s") 
sim=openbugs(data=data1,parameters=parameters1, 
inits=NULL,model.file="model.bivRE.txt", 
     n.chains=1, n.iter=2000, n.burnin=1000, 
     n.thin=1, 
     n.sims = 2000,      
     bugs.directory="C:/Program Files (x86)/OpenBUGS/OpenBUGS323/", 
working.directory = NULL, over.relax = FALSE, seed=NULL) 
# a txt file with the model, named model.bivRE must be included in 
the working directory 
# make sure the path file for OpenBUGS is correctly specified 
 
print(sim) 
plot(sim) 
 
The following code can be used to fit the model of Equation (2) in the main paper, in a frequentist 
setting: 
library(lme4) 
y =c( 5, 5, 6, 0, 0, 0, 2, 2, 0, 1, 2, 3,1,1,  1, 3, 2, 2, 4, 3, 3, 0,12, 
0, 8, 8, 2, 2, 0, 0,16, 3, 0, 0, 0, 3,0,0,  2, 3, 6, 3,12,21, 1, 0,23, 0) 
n =c(63,23,44,128,99,85,30,74,47,24,46,45,32,50, 25,60,20, 82,84,53,16, 
8,34,97,63,22,35,60,77,91,31,76,54,24,44,35,36,50, 25,60,20,65,85,52,16, 
9,36,95)  
stud=c(1:24, 1:24) 
treat=c(rep(0,24), rep(1,24)) 
treat.s=treat-0.5 
gmFE <- glmer(cbind(y, n - y)~treat.s+(1|stud), family = 
binomial(link="logit")) ### fixed effects 
gmFE 
exp(-confint(gmFE,method="Wald")) 
 
gmRE <- glmer(cbind(y, n - y)~treat.s+(1|stud)+(1|stud:treat.s), family = 
binomial(link="logit")) ### random effects 
gmRE 
 exp(-confint(gmRE,method="Wald")) 
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